Enoxaparin sodium biosimilar (Biocad)

依诺肝素钠生物类似药 (Biocad)

Report date: 2022/07/19 20:00:45

Base Information

Drug NameEnoxaparin sodium biosimilar (Biocad)
Drug Alias Name依诺肝素钠生物仿制药 (Biocad)Enoxaparin biosimilar - BiocadEnoxaparinum natricum (Biocad)BCD-080
ClassificationBiologics > BiosimilarNatural product/Extract > Animal extract
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsVenous Thrombosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBIOCAD JSC
Active IndicationsN/A
Inactive IndicationsVenous Thrombosis

Other Information

ATC CodeB01AB05
Related LinksN/A